Completed PHASE3 INTERVENTIONAL 1-arm NCT01556646

Effect of Tolvaptan on Cognitive Function in Cirrhosis

Effects of Tolvaptan on Cognitive Function, Brain Metabolism and Quality of Life in Hyponatremic Cirrhotics With Hepatic Encephalopathy: A Prospective Clinical Trial

Sponsor: Hunter Holmes Mcguire Veteran Affairs Medical Center

Conditions Cirrhosis Hepatic Encephalopathy Hyponatremia

Interventions Tolvaptan

Updated 5 times since 2017 Last updated: Feb 6, 2014 Started: Apr 30, 2011 Primary completion: Jun 30, 2013 Completion: Jun 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Cirrhosis and Hepatic Encephalopathy and is currently completed. Hunter Holmes Mcguire Veteran Affairs Medical Center leads this study, which shows 5 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Apr 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hunter Holmes Mcguire Veteran Affairs Medical Center
Otsuka America Pharmaceutical

Data source: Hunter Holmes Mcguire Veteran Affairs Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Richmond, United States